GlassScriptPhysician profile
Mary E Price
NPI 1568830461
$2,140.52
in general payments reported to CMS, 2019-2025
29 companies · $16.81 in 2025
The $16.81 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $660 · 2022: $888 · 2023: $523 · 2024: $51.78 · 2025: $16.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $476.17 | 2021-2025 | Smartvest |
| Glaxosmithkline, LLC. | $215.68 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.91 | 2021-2022 | |
| Philips North America LLC | $158.58 | 2022 | |
| Abbvie INC. | $138.22 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $104.30 | 2021-2022 | |
| United Therapeutics Corporation | $89.27 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.97 | 2023 | |
| Genzyme Corporation | $76.05 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $65.72 | 2023 | Rexulti, Abilify Maintena |
| Mylan Specialty L.P. | $62.84 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $57.27 | 2023 | Austedo, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $50.92 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $46.77 | 2022 | |
| Lundbeck LLC | $40.67 | 2023 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $40.03 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $27.32 | 2022 | |
| Insmed, INC. | $26.62 | 2021-2022 | |
| Axsome Therapeutics, INC. | $21.04 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $20.96 | 2023 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $20.50 | 2023 | Spravato |
| Alkermes, INC. | $20.01 | 2023 | Aristada, Lybalvi |
| Bayer Healthcare Pharmaceuticals INC. | $18.68 | 2022 | |
| La Jolla Pharmaceutical Company | $18.08 | 2021 | |
| Mallinckrodt Hospital Products INC. | $16.58 | 2021 | |
| Harmony Biosciences LLC | $16.02 | 2022 | |
| Amgen INC. | $15.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.71 | 2021 | |
| Advanced Respiratory, INC | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.